Urogen Pharma: New Bladder Cancer Drugs Expected to Drive 69% Annual Revenue Growth

Urogen has achieved annual revenue growth since 2020. Since 2022, this has been reflected in a sustained increase in the stock price, which reached a three-year high on November 12, 2025. The company specializes in the treatment of urothelial carcinoma, which consists of cancer cells originating from the urothelium, the specialized mucosal layer lining the bladder, ureters, and renal pelvis. Many tumors recur after treatment or may transition to muscle-invasive forms, which are significantly harder to treat. Accordingly, a lasting and targeted treatment...